Is tirzepatide the same as Ozempic®?

Tirzepatide isn’t the same as Ozempic^®, though these two medications are related and share similarities. Ozempic^® contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, as its main active ingredient. However, tirzepatide is both a glucose-dependent insulinotropic polypeptide (GIP) agonist and a GLP-1 receptor agonist, with a different mechanism of action than Ozempic^®.

Though a licensed healthcare provider may prescribe either tirzepatide and Ozempic^® to support blood sugar control and weight-management efforts, they aren’t the same medication and can’t be used interchangeably. If you’re interested in using these drugs as part of a broader care plan, you’ll need to see a licensed healthcare provider who can conduct a clinical evaluation and review your medical history to find the right one for your needs.

Here’s what you should know about tirzepatide, Ozempic^®, and the main differences between these two similar medications.

What is Ozempic^® (semaglutide)?

Ozempic^®, much like Wegovy^®, is a brand-name medication containing semaglutide, a GLP-1 receptor agonist. Semaglutide mimics the GLP-1 hormone that the body naturally releases after eating. GLP-1 is important for several digestion-related bodily functions, including appetite and blood sugar regulation.

When blood sugar is elevated, such as after a meal, GLP-1 increases insulin release. This lowers blood sugar levels. It also reduces the production of glucagon—a hormone that works to increase your blood sugar—and slows the rate at which the stomach empties. This decreased gastric emptying helps keep blood sugar levels low and may contribute to increased feelings of fullness in some individuals.

Compounded semaglutide, typically administered as an injectable, is sometimes used in clinical settings under provider supervision and may have similar impacts on blood sugar regulation and appetite. This is why semaglutide medications like Ozempic^® have been studied for weight management as well as diabetes management.

What is the FDA-approved use of Ozempic^®?

The U.S. Food and Drug Administration (FDA) has approved several uses for Ozempic^®. 

Ozempic^® is FDA-approved to treat type 2 diabetes in certain adults and to reduce the risk of major cardiovascular events in certain adults. This includes adults with type 2 diabetes and established cardiovascular disease. In addition, the FDA has approved Ozempic^® for certain patients to support kidney-related outcomes associated with type 2 diabetes.

Other semaglutide medications, specifically Wegovy^®, have been FDA-approved for chronic weight management in eligible adults. The FDA has yet to approve Ozempic^® for this purpose. However, it’s worth noting that research into GLP-1 medications is ongoing. 

What is tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It’s commonly sold under brand names approved for different uses: Mounjaro^® (for type 2 diabetes management) and Zepbound^® (for chronic weight management). Similar to semaglutide, compounded tirzepatide may be prescribed and administered under medical supervision, often as an injection.

Unlike semaglutide, tirzepatide activates both the GIP and GLP-1 hormone pathways. This suggests it may have many of the same effects on the body as semaglutide, in addition to mimicking the effects of the GIP hormone. GIP stimulates insulin secretion, helping regulate blood sugar, and also plays a role in appetite control. The dual mechanisms of GIP and GLP-1 have been studied for their potential to support blood sugar regulation and weight management in clinical settings.

What is the FDA-approved use of tirzepatide?

The FDA has also approved several uses of tirzepatide. Under the brand name Mounjaro^®, tirzepatide is FDA-approved to treat type 2 diabetes in adults, as well as children aged 10 years or older.

As Zepbound^®, tirzepatide is FDA-approved for chronic weight management in eligible adults with obesity. The FDA has approved it for overweight adults who have at least one weight-related condition. At the end of 2024, the FDA approved Zepbound^® for treating obstructive sleep apnea in adults with obesity, too.

Key differences between tirzepatide and Ozempic^®

Despite their many common characteristics, medications like Ozempic^®, Wegovy^®, and Mounjaro^® differ in a few key ways. Some of the main differences between tirzepatide and Ozempic include:

• Active ingredients: Semaglutide is the active ingredient in Ozempic^® and Wegovy^®, while tirzepatide is the active ingredient in Mounjaro^® and Zepbound^®.
• Drug class: As a GLP-1 agonist, Ozempic^® is in a different drug or pharmacological class than tirzepatide, which is classified as a dual GIP/GLP-1 agonist.
• Hormone pathways targeted: Though both Ozempic^® and tirzepatide target the GLP-1 hormone receptor, tirzepatide also targets the GIP receptor.
• Typical dosing structure and titration: Ozempic^® and tirzepatide are injections, but the dosage and titration schedule differ for each drug. 

It’s always best to work with a licensed healthcare provider to determine which medication may best suit your specific needs and health goals.

Which medication is more effective for weight loss?

Both semaglutide- and tirzepatide-based drugs have been studied for their potential to support weight loss and weight management. One study of adults who are overweight or who have obesity found that participants lost 15% of their body weight when taking weekly semaglutide injections. However, a separate study of adults who are overweight or who have obesity took tirzepatide weekly and lost between 15% and 21% of their body weight.

In some head-to-head studies, participants on average lost more weight when taking tirzepatide than when taking semaglutide. These findings suggest that tirzepatide may be associated with greater weight loss in certain populations. However, this doesn’t mean semaglutide is ineffective for weight loss or weight management.

Individual results vary, and these medications are not appropriate for everyone. Depending on your unique circumstances, one drug may be a better fit for you than another. The efficacy of each drug, as well as your eligibility to take them, will depend on your medical history and a clinical evaluation from a licensed healthcare provider.

Can you switch between tirzepatide and Ozempic^®?

You can switch between tirzepatide and Ozempic^®, but you can’t do so on your own. Switching from one GLP-1 drug to another requires guidance from a licensed healthcare provider and an appropriate clinical evaluation.

These medications aren’t directly interchangeable. They have different molecular structures and mechanisms that promote weight loss in similar yet ultimately distinct ways. It’s possible that, even if one works for you, another might not, or could even result in serious side effects or complications. Each GLP-1 drug has its own recommended dosage and titration schedule to achieve therapeutic effects. 

A medical provider can help you decide on the right drug for your needs, the best titration schedule for your goals, identify when it’s time to consider a switch to something else (such as if you hit a weight loss plateau), and help you make that switch safely. 

Which one is right for you?

Only a licensed healthcare provider can help determine if tirzepatide or semaglutide is right for you. However, you can consider some of the following factors and discuss them during a clinical evaluation:

• Whether you have type 2 diabetes or any weight-related health conditions
• What your weight-loss goals are
• Your ability to tolerate side effects
• What your insurance will cover
• Your medical history

You can have ongoing conversations with your provider about how the drug is affecting you and your health to maximize its effectiveness for your goals and minimize its side effects. This is essential to maintaining your overall health and wellness while achieving your weight-loss goals.

If you’re interested in taking steps toward improving your health, Shed connects members with licensed healthcare providers who can conduct clinical evaluations and determine whether a prescription for a weight-loss drug is medically appropriate for you. Sign up today to get started!

Important information about safety and side effects: Both semaglutide and tirzepatide have caused thyroid C-cell tumors in rodents. It is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Do not take these medications if you or any family member have ever had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Serious side effects may include pancreatitis (severe abdominal pain), gallbladder problems, low blood sugar, kidney injury, serious allergic reactions, and severe gastrointestinal disease. See Shed’s Help Center for more information on common GLP-1 side effects.

FAQs about tirzepatide and Ozempic^®

Is tirzepatide stronger than Ozempic^®?

Tirzepatide is not necessarily “stronger,” but it works differently. Because it activates both GIP and GLP-1 receptors, some clinical trials have shown greater average weight loss and A1C reduction compared to semaglutide (the active ingredient in Ozempic^®). However, effectiveness depends on dosage, individual metabolism, and medical history. What works best varies from person to person, which is why a healthcare provider must determine the most appropriate option.

Is Mounjaro^® the same as Ozempic^®?

No. Mounjaro^® contains tirzepatide, while Ozempic^® contains semaglutide. Although both are weekly injectable medications used to improve blood sugar control, they contain different active ingredients and work on different hormone pathways. They are part of the same broader class of incretin-based therapies, but are not the same drug.

Is Zepbound^® the same as Ozempic^®?

No. Zepbound^® contains tirzepatide and is FDA-approved for chronic weight management. Ozempic^® contains semaglutide and is FDA-approved for type 2 diabetes. While both medications can support weight loss, they have different official indications and slightly different mechanisms of action.

Can you switch from Ozempic^® to tirzepatide?

Switching is possible in some cases, but you must do it under medical supervision. Because these medications differ in structure, receptor activity, and dosing schedules, transitioning between them requires a provider to determine appropriate timing and titration. Self-adjusting or switching without guidance can increase the risk of side effects.

Why do both medications cause weight loss?

Both medications influence hormones involved in appetite and blood sugar regulation. By slowing gastric emptying and affecting hunger signals in the brain, they may help reduce calorie intake. Improved insulin sensitivity and better blood sugar control may also support metabolic changes that contribute to weight loss.

Are tirzepatide and semaglutide the same type of drug?

They are related but not identical. Semaglutide is a GLP-1 receptor agonist, meaning it targets one incretin hormone pathway. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two pathways. This distinction is central to how their effects may differ in clinical outcomes.

Do tirzepatide and Ozempic^® have the same side effects?

They share many common side effects, particularly gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. However, the frequency and intensity of these effects can vary. Both medications also carry warnings for rare but serious risks, including pancreatitis and thyroid C-cell tumors.

Which medication is better for weight loss if I don’t have diabetes?

The answer depends on individual health factors and FDA approvals. The FDA has approved tirzepatide (under certain brand names) for chronic weight management, while they’ve approved Ozempic^® for type 2 diabetes. A healthcare provider will evaluate BMI, medical history, and treatment goals to determine the most appropriate option.

Are these medications interchangeable at the pharmacy?

No. They are different prescription medications with different active ingredients and approved uses. Even though they are both weekly injections, they cannot be substituted for one another without a provider issuing a new prescription and overseeing the transition.

‍

Disclaimer:
This content is provided for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. You should consult a licensed healthcare provider for evaluation and guidance specific to your situation before starting or changing any treatment, supplement, or medication.

Compounded medications are not FDA-approved for safety, effectiveness, or quality. They are prepared by a licensed pharmacy based on a provider's prescription. Results may vary.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk. Shed is not affiliated with or endorsed by Novo Nordisk.

Zepbound^® and Mounjaro® are registered trademarks of Eli Lilly and Company. Shed is not affiliated with or endorsed by Eli Lilly and Company.

Shed is not a pharmacy and does not dispense medications. Prescriptions are fulfilled and shipped by a licensed third-party dispensing pharmacy.